Brief: Galmed Announces Positive Results Of Phase 1 Study Of AMILO-5MER
Galmed Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary
U.S. STOCKS ON THE MOVE-51job, Gaotu Techedu, Coty, Tesla
Galmed jumps on promising new data on liver disease drug
Brief: Galmed Pharma Provides Additional Positive Data From The Open Label Part Of ARMOR Study And Reports Q3 2021 Financial Results
Brief: Galmed Announces New Positive Data From Ongoing Study Open Label Part Showing Clinically Significant Effect On Fibrosis Improvement
Brief: Galmed Announces Positive Results From First 16 Patients In Open-Label Part Of Armor Study
Brief: Results Of Galmed's Phase 2B Arrest Trial Of Aramchol Published In Nature Medicine
Publication In " Journal Of Autoimmunity" For Its Anti-Inflammatory Compound, Amilo-5Mer
Brief: MHRA Agrees With Galmed's Plan To Use Aramchol Meglumine In Part Of Phase 3 Study
Galmed Pharmaceuticals Ltd reports results for the quarter ended in June - Earnings Summary
Galmed Pharmaceuticals Ltd expected to post a loss of 38 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Square, Affirm, Foot Locker, Tesla, Robinhood
Galmed Pharma rises as FDA greenlights change in NASH trial
Brief: FDA Agrees With Galmed's Plan To Use Aramchol Meglumine
Galmed Pharmaceuticals Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Galmed Pharmaceuticals - Q1 Loss Per Share Of $0.38
Galmed Pharmaceuticals Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Galmed Announces Approval Of Ind Application In China For Aramchol For The Treatment Of Nash & Fibrosis In The Global Phase 3 Armor Registrational Study